Notizie AIOM – anno XVII – Pagina 63

23 Aprile 2019

American Cancer Society Report Finds Application of Cancer-Reducing Strategies in the United States Is Suboptimal

April 15, 2019 - The latest edition of the American Cancer Society’s (ACS) review on recent cancer prevention and early detection efforts has found that although many strategies have been proven to reduce cancer risk, their application has been suboptimal in the United ...
Leggi tutto

23 Aprile 2019

ASTRO Radiation Oncologist Workforce Study Shows Demographic Shifts

April 15, 2019 - The newest study of America’s radiation oncologist workforce finds that gender and racial gaps have narrowed slightly, although persistent and growing geographic disparities point to a need for more equity in access to radiation therapy care. The survey ...
Leggi tutto

23 Aprile 2019

ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents

April 17, 2019 - ASCO and the American Society of Hematology (ASH) have released an update to existing guidelines for the use of erythropoiesis-stimulating agents to manage anemia in patients with cancer. The update was simultaneously published in the Journal of Clinical ...
Leggi tutto

23 Aprile 2019

Atezolizumab Approval Sets Stage for Future Drug Development in TNBC

April 18, 2019 - The impact of the March 2019 FDA approval of atezolizumab plus nab-paclitaxel in patients with locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC) is unmistakable, but according to Mariana Chavez Mac Gregor, MD, MSc, ...
Leggi tutto

23 Aprile 2019

FDA Schedules ODAC Meetings for Pexidartinib in TGCT and Quizartinib in AML

April 19, 2019 - The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for May 14, 2019, to discuss a new drug application (NDA) for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor. The agency also scheduled ...
Leggi tutto

19 Aprile 2019

19 aprile 2019 – Modifica del regime di fornitura di medicinali per uso umano approvati per procedura centralizzata a base del principio attivo Pregabalin

19 Aprile 2019

Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer

Previous studies have shown that continued smoking among patients with cancer can increase overall and cancer-specific mortality, risk for second primary cancer, and risk for toxic effects of cancer treatment. To our knowledge, there have been no efforts to estimate additional ...
Leggi tutto

19 Aprile 2019

Survival Impact of Optimal Surgical Cytoreduction in Recurrent Epithelial Ovarian Cancer with Brain Metastasis

The aim of this study was to determine the clinicopathological characteristics, treatment details and outcome of patients with brain metastasis from epithelial ovarian carcinoma (EOC). This study included 21 patients diagnosed with brain metastasis from EOC between 1999 ...
Leggi tutto

19 Aprile 2019

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract

Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ineligible for the pivotal IMvigor211 phase 3 trial of atezolizumab. ...
Leggi tutto

19 Aprile 2019

18 aprile 2019 – FDA approva un nuovo trattamento per l’osteoporosi nelle donne in postmenopausa

LAVORIAMO CON

News

LA PREVENZIONE DEL MELANOMA: AL VIA UNA CAMPAGNA NEI COOP.FI

TUMORI: “AIFA APPROVA LA FORMULAZIONE SOTTOCUTANEA E TRE NUOVE INDICAZIONI TERAPEUTICHE DI NIVOLUMAB”

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

Notizie AIOM – anno XVII

American Cancer Society Report Finds Application of Cancer-Reducing Strategies in the United States Is Suboptimal

ASTRO Radiation Oncologist Workforce Study Shows Demographic Shifts

ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents

Atezolizumab Approval Sets Stage for Future Drug Development in TNBC

FDA Schedules ODAC Meetings for Pexidartinib in TGCT and Quizartinib in AML

19 aprile 2019 – Modifica del regime di fornitura di medicinali per uso umano approvati per procedura centralizzata a base del principio attivo Pregabalin

Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer

Survival Impact of Optimal Surgical Cytoreduction in Recurrent Epithelial Ovarian Cancer with Brain Metastasis

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract

18 aprile 2019 – FDA approva un nuovo trattamento per l’osteoporosi nelle donne in postmenopausa